We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 2,426

The Supreme Court restores the role of the district court in claim construction

  • Vedder Price PC
  • -
  • USA
  • -
  • January 30 2015

In a 7-2 decision, the Supreme Court held that not all determinations made during the process of claim construction are reviewed de novo upon appeal

Equivocally bioequivalent - the Federal Court opens the door for consumer law challenges by innovators

  • Corrs Chambers Westgarth
  • -
  • Australia
  • -
  • January 30 2015

A recent preliminary discovery decision of Justice Beach of the Federal Court of Australia may have made life that little bit harder for generic

Patents vs. Data Exclusivity in pharmaceuticals

  • Tsai Lee & Chen Patent Attorneys & Attorneys at Law
  • -
  • Taiwan
  • -
  • January 29 2015

Characteristics of the Pharmaceutical IndustryBringing a new drug to market requires the investment of a great deal of time and money in research and

Why did the Supreme Court GVR the Shire Lialda case?

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 29 2015

On January 26, 2015, the Supreme Court granted certiorari, vacated, and remanded Shire Development LLC v. Watson Pharmaceuticals, Inc., to the

Federal Circuit to Myriad: neither DNA primers nor comparing gene sequences are patent-eligible subject matter

  • McDermott Will & Emery
  • -
  • USA
  • -
  • January 29 2015

In the latest decision addressing the patentability of Myriad’s BRCA1- and BRCA2-related patents, the U. S. Court of Appeals for the Federal Circuit

Supreme Court: claim construction is subject to hybrid review

  • McDermott Will & Emery
  • -
  • USA
  • -
  • January 29 2015

In a 72 decision penned by Justice Breyer, the Supreme Court of the United States overturned the de novo standard as the sole standard of review

No declaratory jurisdiction without biosimilarity application on file with FDA

  • McDermott Will & Emery
  • -
  • USA
  • -
  • January 29 2015

Avoiding an interpretation of the Biologics Price Competition and Innovation Act (BPCIA), the U.S. Court of Appeals for the Federal Circuit invoked

Parthenotes are not stem cells, rules CJEU

  • Mewburn Ellis LLP
  • -
  • European Union
  • -
  • January 28 2015

In decision C 36413 ISCO v. Comptroller handed down on 18 December 2014, the Court of Justice of the European Union (CJEU) decided that unfertilised

Old drugs, new tricks: patent considerations in drug repurposing

  • Mewburn Ellis LLP
  • -
  • European Union, United Kingdom
  • -
  • January 28 2015

The drug discovery and development path for a New Chemical Entity (NCE) can take 10 to 15 years and cost 1 to 2 billion dollars. Repurposing is the

Validity of Sequenom patent still to be decided

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 27 2015

Although Sequenom has settled its dispute over U.S. Patent 6,258,540 with some parties (as I noted here), its case against Ariosa Diagnostics, Inc